Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 06'th Jan 2025
SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
02:53pm, Monday, 06'th Jan 2025
JPMorgan has reset the valuation for Viking Therapeutics Inc. VKTX and Structure Therapeutics Inc. GPCR.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Monday, 06'th Jan 2025
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors a
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts
11:11am, Monday, 06'th Jan 2025
In this video, I will cover the recent updates regarding Viking Therapeutics (VKTX 1.26%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Sunday, 05'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are a
Why Viking Therapeutics Stock Plummeted by 24% in December
04:23pm, Saturday, 04'th Jan 2025
Viking Therapeutics (VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a rival's ag
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Friday, 03'rd Jan 2025
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ad
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
10:46am, Friday, 03'rd Jan 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Should You Buy the Dip on This High-Flying Stock?
08:00am, Friday, 03'rd Jan 2025
It's been an excellent year for Viking Therapeutics (VKTX 2.19%), a mid-cap biotech company. Thanks to impressive mid-stage clinical results, its stock skyrocketed in February.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
10:20am, Thursday, 02'nd Jan 2025
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
07:21am, Thursday, 02'nd Jan 2025
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
06:55pm, Tuesday, 31'st Dec 2024
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $40.25, indicating a +1.19% shift from the previous trading day.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Tuesday, 31'st Dec 2024
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
01:30pm, Monday, 30'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
01:07pm, Sunday, 29'th Dec 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX NEW YORK, December 27, 2024 (PRNEWSWIRE)Pomerantz LLP is investigating claims on be
